Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H11F3N2O3 |
Molecular Weight | 276.2123 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C(=Nc1ccc(c(c1)C(F)(F)F)N(=O)=O)O
InChI
InChIKey=MKXKFYHWDHIYRV-UHFFFAOYSA-N
InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
Molecular Formula | C11H11F3N2O3 |
Molecular Weight | 276.2123 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00499Curator's Comment:: Description was created based on several sources, including
https://www.drugs.com/pro/flutamide.html
Sources: http://www.drugbank.ca/drugs/DB00499
Curator's Comment:: Description was created based on several sources, including
https://www.drugs.com/pro/flutamide.html
Flutamide is a nonsteroidal antiandrogen. In animal studies, flutamide demonstrates potent antiandrogenic effects. It exerts its antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding of androgen in target tissues or both. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen, e.g. castration. Elevations of plasma testosterone and estradiol levels have been noted following flutamide administration. Flutamide blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor. In addition Flutamide is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen. Flutamide is used for the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6055125
Curator's Comment:: flutamide crosses the blood brain barrier and is capable of exerting influence on central structures through interactions with androgen receptors.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL612518 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21600678 |
0.9 µM [IC50] | ||
Target ID: CHEMBL1871 Sources: http://www.drugbank.ca/drugs/DB00499 |
102.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | EULEXIN Approved UseFlutamide capsules are indicated for use in combination with LHRH agonists for the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate. Launch Date6.01776E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
53.4 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10073738 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
112.7 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2754024 |
250 mg 3 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
25.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2754024 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
96.4 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10073738 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
212.1 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2754024 |
250 mg 3 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
63 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2754024 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10073738 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUTAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Disc. AE: Abdominal pain, Vomiting... Other AEs: Flatulence, Diarrhea... AEs leading to discontinuation/dose reduction: Abdominal pain (12 patients) Other AEs:Vomiting (8 patients) Headache (9 patients) Hypertransaminasemia (3 patients) Fatty liver (1 patient) Weight gain (5 patients) Flatulence (15 patients) Sources: Diarrhea (5 patients) Dry skin (10 patients) Nephrolithiasis (1 patient) Leg pain (2 patients) Dyslipidemia (4 patients) Fluid retention (4 patients) Epigastralgia (3 patients) Dyspepsia (2 patients) Nausea (9 patients) Vaginal infection (1 patient) Constipation (3 patients) |
250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Disc. AE: Diarrhea, Impaired liver function... Other AEs: Hot flushes, Breast tenderness... AEs leading to discontinuation/dose reduction: Diarrhea (severe, 1.3%) Other AEs:Impaired liver function (4%) Gynecomastia (1.3%) Hot flushes (all grades, 25%) Sources: Breast tenderness (all grades, 49%) Nausea and vomiting (all grades, 22%) Appetite lost (all grades, 17%) Diarrhea (all grades, 16%) Hot flushes (severe, 4%) Breast tenderness (severe, 7%) Nausea and vomiting (severe, 1.3%) Appetite lost (severe, 1.3%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nephrolithiasis | 1 patient | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Vaginal infection | 1 patient | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Fatty liver | 1 patient Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Dry skin | 10 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Abdominal pain | 12 patients Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Flatulence | 15 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Dyspepsia | 2 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Leg pain | 2 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Constipation | 3 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Epigastralgia | 3 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Hypertransaminasemia | 3 patients Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Dyslipidemia | 4 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Fluid retention | 4 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Diarrhea | 5 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Weight gain | 5 patients Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Vomiting | 8 patients Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Nausea | 9 patients | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Headache | 9 patients Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Co-administed with:: ethinyl estradiol(0.020 mg) Sources: desogestrel(0.15 mg) |
unhealthy, 26.3 n = 83 Health Status: unhealthy Condition: hirsutism Age Group: 26.3 Sex: F Population Size: 83 Sources: |
Gynecomastia | 1.3% Disc. AE |
250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Impaired liver function | 4% Disc. AE |
250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Diarrhea | all grades, 16% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Appetite lost | all grades, 17% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Nausea and vomiting | all grades, 22% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Hot flushes | all grades, 25% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Breast tenderness | all grades, 49% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Appetite lost | severe, 1.3% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Nausea and vomiting | severe, 1.3% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Diarrhea | severe, 1.3% Disc. AE |
250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Hot flushes | severe, 4% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Breast tenderness | severe, 7% | 250 mg 3 times / day multiple, oral Recommended Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 75 Health Status: unhealthy Condition: prostate cancer Age Group: adult Sex: M Population Size: 75 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
unlikely | ||||
unlikely | ||||
yes [Ki 1 uM] | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/18599551/ |
||||
PubMed
Title | Date | PubMed |
---|---|---|
Effects of an environmental anti-androgen on erectile function in an animal penile erection model. | 2000 Apr |
|
Examination of selected food additives and organochlorine food contaminants for androgenic activity in vitro. | 2000 Feb |
|
Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. | 2000 Jan |
|
Ultrastructural and quantitative immunohistochemical changes induced by nonsteroid antiandrogens on pituitary gonadotroph population of prepubertal male rats. | 2001 |
|
Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. | 2001 |
|
[Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials]. | 2001 Apr |
|
Sodium-induced rise in blood pressure is suppressed by androgen receptor blockade. | 2001 Apr |
|
The effects of intrahippocampal testosterone and flutamide on spatial localization in the Morris water maze. | 2001 Apr 6 |
|
Androgen-induced up-regulation of tubulin isoforms in neuroblastoma cells. | 2001 Aug |
|
Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. | 2001 Aug |
|
Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. | 2001 Aug |
|
Testosterone suppresses spermatogenesis in juvenile spermatogonial depletion (jsd ) mice. | 2001 Aug |
|
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. | 2001 Aug 1 |
|
Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. | 2001 Aug 5 |
|
Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. | 2001 Feb 23 |
|
Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism. | 2001 Feb 23 |
|
[Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report]. | 2001 Jan |
|
Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. | 2001 Jan |
|
An electrochemical evidence of free radicals formation from flutamide and its reactivity with endo/xenobiotics of pharmacological relevance. | 2001 Jan |
|
Lack of methemoglobinemia with flutamide. | 2001 Jan |
|
Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. | 2001 Jan |
|
Androgen-dependent regulation of human angiotensinogen expression in KAP-hAGT transgenic mice. | 2001 Jan |
|
Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. | 2001 Jan |
|
Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. | 2001 Jan 1 |
|
Sexual dimorphism and aromatase in the rat retina. | 2001 Jan 31 |
|
Virilization of the urogenital sinus of the tammar wallaby is not unique to 5alpha-androstane-3alpha,17beta-diol. | 2001 Jul 5 |
|
Kap promoter analysis in vivo: a regulatory role for a truncated L1 repeat. | 2001 Jul 5 |
|
Strain sensitivity differences in the Hershberger assay. | 2001 Jul-Aug |
|
Steroid-sensitive gene-1 is an androgen-regulated gene expressed in prostatic smooth muscle cells in vivo. | 2001 Jun |
|
Modulation of gene expression by androgen and oestrogens in the testis and prostate of the adult rat following androgen withdrawal. | 2001 Jun 10 |
|
Testosterone perturbs epidermal permeability barrier homeostasis. | 2001 Mar |
|
Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. | 2001 Mar 15 |
|
Administration of tamoxifen but not flutamide to hormonally intact, adult male rats mimics the effects of short-term gonadectomy on the catecholamine innervation of the cerebral cortex. | 2001 Mar 19 |
|
Suppression of androgen action and the induction of gross abnormalities of the reproductive tract in male rats treated neonatally with diethylstilbestrol. | 2001 Mar-Apr |
|
[Complete remission of brain metastases from prostate cancer by gamma knife radiosurgery: a case report]. | 2001 May |
|
Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. | 2001 May |
|
Effects of acute stanozolol treatment on puberty in female rats. | 2001 May |
|
Dissection and weighing of accessory sex glands after formalin fixation, and a 5-day assay using young mature rats are reliable and feasible in the Hershberger assay. | 2001 May 11 |
|
Chemical andropause and amyloid-beta peptide. | 2001 May 2 |
|
Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. | 2001 May 24 |
|
Quantification of antiandrogen effect determined by Lightcycler technology. | 2001 May 28 |
|
Possible androgenic/anti-androgenic activity of the insecticide fenitrothion. | 2001 May-Jun |
|
Neonatal exposure to potent and environmental oestrogens and abnormalities of the male reproductive system in the rat: evidence for importance of the androgen-oestrogen balance and assessment of the relevance to man. | 2001 May-Jun |
|
Tamoxifen is an acute, estrogen-like, coronary vasodilator of porcine coronary arteries in vitro. | 2001 Nov |
|
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. | 2001 Nov 1 |
|
Replacement of surgical castration by GnRH-inhibition or Leydig cell ablation in the male rat Hershberger antiandrogen assay. | 2001 Oct |
|
Attenuation of vascular endothelial dysfunction by testosterone receptor blockade after trauma and hemorrhagic shock. | 2001 Oct |
|
Flutamide-induced acute hepatitis in advanced prostate cancer patients. | 2001 Sep |
|
Differential gene expression in response to methoxychlor and estradiol through ERalpha, ERbeta, and AR in reproductive tissues of female mice. | 2001 Sep |
|
Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. | 2001 Sep 5 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/flutamide.html
For use in locally confined stage B2-C and stage D2 metastatic carcinoma of the prostate: 250 mg orally every 8 hours.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19307032
Flutamide inhibited spiggin production in vitro at a concentration as low as 10(-12) M in cultures of primed female stickleback kidney cells
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 20:55:42 UTC 2021
by
admin
on
Fri Jun 25 20:55:42 UTC 2021
|
Record UNII |
76W6J0943E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175560
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
||
|
WHO-ATC |
L02BB01
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
||
|
NDF-RT |
N0000000243
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
||
|
NCI_THESAURUS |
C242
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
||
|
NCI_THESAURUS |
C1915
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
||
|
WHO-VATC |
QL02BB01
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
||
|
LIVERTOX |
429
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
FLUTAMIDE
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | |||
|
DB00499
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | |||
|
M5508
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | Merck Index | ||
|
CHEMBL806
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | |||
|
4508
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | RxNorm | ||
|
236-341-9
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | |||
|
1285851
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | USP-RS | ||
|
13311-84-7
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | |||
|
1223
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | |||
|
3483
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | |||
|
3397
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | |||
|
D005485
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | |||
|
6943
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | |||
|
76W6J0943E
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | |||
|
13311-84-7
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | |||
|
C509
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY | |||
|
SUB07756MIG
Created by
admin on Fri Jun 25 20:55:42 UTC 2021 , Edited by admin on Fri Jun 25 20:55:42 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (UV)
EP
|
||
|
BINDER->LIGAND |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TARGET -> INHIBITOR |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||